{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:40:04Z","timestamp":1746794404461,"version":"3.40.5"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100024252","name":"Facult\u00e9 de pharmacie, Universit\u00e9 de Montr\u00e9al","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024252","id-type":"DOI","asserted-by":"publisher"}]},{"name":"R\u00e9seau de recherche en Sant\u00e9 Respiratoire du Qu\u00e9bec"},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40262-025-01505-4","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T03:00:22Z","timestamp":1745204422000},"page":"631-653","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-infectives in Pediatric Patients with Cystic Fibrosis: A Comprehensive Review of Population Pharmacokinetic Analyses"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0447-7668","authenticated-orcid":false,"given":"Aysenur","family":"Yaliniz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"El Hassani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana C.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Marsot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"1","key":"1505_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1891\/NN-2022-0007","volume":"42","author":"H Myer","year":"2023","unstructured":"Myer H, Chupita S, Jnah A. Cystic fibrosis: back to the basics. Neonatal Netw. 2023;42(1):23\u201330.","journal-title":"Neonatal Netw"},{"key":"1505_CR2","volume-title":"The Canadian cystic fibrosis registry 2022 annual data report","author":"CF Canada","year":"2023","unstructured":"Canada CF. The Canadian cystic fibrosis registry 2022 annual data report. Toronto: Cystic Fibrosis Canada; 2023."},{"issue":"18","key":"1505_CR3","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMra2216474","volume":"389","author":"H Grasemann","year":"2023","unstructured":"Grasemann H, Ratjen F. Cystic fibrosis. N Engl J Med. 2023;389(18):1693\u2013707.","journal-title":"N Engl J Med"},{"issue":"2","key":"1505_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1542\/pir.2019-0212","volume":"42","author":"KM Dickinson","year":"2021","unstructured":"Dickinson KM, Collaco JM. Cystic fibrosis. Pediatr Rev. 2021;42(2):55\u201367.","journal-title":"Pediatr Rev"},{"issue":"21","key":"1505_CR5","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1001\/jama.2023.8120","volume":"329","author":"T Ong","year":"2023","unstructured":"Ong T, Ramsey BW. Cystic fibrosis: a review. JAMA. 2023;329(21):1859\u201371.","journal-title":"JAMA"},{"issue":"1","key":"1505_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1183\/09031936.00159111","volume":"40","author":"V Waters","year":"2012","unstructured":"Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J. 2012;40(1):61\u20136.","journal-title":"Eur Respir J"},{"issue":"4","key":"1505_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1023\/A:1008634911114","volume":"20","author":"DJ Touw","year":"1998","unstructured":"Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci. 1998;20(4):149\u201360.","journal-title":"Pharm World Sci"},{"issue":"8","key":"1505_CR8","first-page":"1258","volume":"9","author":"IM Ciuca","year":"2022","unstructured":"Ciuca IM, Dediu M, Popin D, Pop LL, Tamas LA, Pilut CN, et al. Antibiotherapy in children with cystic fibrosis\u2014an extensive review. Children (Basel). 2022;9(8):1258.","journal-title":"Children (Basel)."},{"issue":"Supplement_2","key":"1505_CR9","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1093\/jpids\/piac071","volume":"11","author":"EC Lloyd","year":"2022","unstructured":"Lloyd EC, Cogen JD, Maples H, Bell SC, Saiman L. Antimicrobial stewardship in cystic fibrosis. J Pediatr Infect Dis Soc. 2022;11(Supplement_2):S53-s61.","journal-title":"J Pediatr Infect Dis Soc."},{"key":"1505_CR10","unstructured":"Foundation CF. 2022 Patient registry annual data report. 2023."},{"issue":"12","key":"1505_CR11","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s40262-020-00932-9","volume":"59","author":"PJ De Sutter","year":"2020","unstructured":"De Sutter PJ, Gasthuys E, Van Braeckel E, Schelstraete P, Van Biervliet S, Van Bocxlaer J, et al. Pharmacokinetics in patients with cystic fibrosis: a systematic review of data published between 1999 and 2019. Clin Pharmacokinet. 2020;59(12):1551\u201373.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1505_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ppul.22757","volume":"48","author":"JT Zobell","year":"2013","unstructured":"Zobell JT, Young DC, Waters CD, Ampofo K, Stockmann C, Sherwin CM, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatr Pulmonol. 2013;48(6):525\u201337.","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"1505_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2165\/00003088-198713040-00002","volume":"13","author":"R de Groot","year":"1987","unstructured":"de Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet. 1987;13(4):228\u201353.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1505_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/17425255.2021.1836157","volume":"17","author":"AM Akkerman-Nijland","year":"2021","unstructured":"Akkerman-Nijland AM, Akkerman OW, Grasmeijer F, Hagedoorn P, Frijlink HW, Rottier BL, et al. The pharmacokinetics of antibiotics in cystic fibrosis. Expert Opin Drug Metab Toxicol. 2021;17(1):53\u201368.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"1505_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.pedhc.2015.07.010","volume":"29","author":"L Molloy","year":"2015","unstructured":"Molloy L, Nichols K. Infectious diseases pharmacotherapy for children with cystic fibrosis. J Pediatr Health Care. 2015;29(6):565\u201378 (quiz 79-80).","journal-title":"J Pediatr Health Care"},{"issue":"3","key":"1505_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bcp.12267","volume":"79","author":"HK Batchelor","year":"2015","unstructured":"Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015;79(3):395\u2013404.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1505_CR17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u201364.","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"1505_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40262-016-0428-x","volume":"56","author":"A Marsot","year":"2017","unstructured":"Marsot A, Guilhaumou R, Riff C, Blin O. Amikacin in critically ill patients: a review of population pharmacokinetic studies. Clin Pharmacokinet. 2017;56(2):127\u201338.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1505_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40262-021-01050-w","volume":"61","author":"A Aljutayli","year":"2022","unstructured":"Aljutayli A, El-Haffaf I, Marsot A, Nekka F. An update on population pharmacokinetic analyses of vancomycin, part II: in pediatric patients. Clin Pharmacokinet. 2022;61(1):47\u201370.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1505_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/jcpt.12850","volume":"44","author":"M Crcek","year":"2019","unstructured":"Crcek M, Zdovc J, Kerec KM. A review of population pharmacokinetic models of gentamicin in paediatric patients. J Clin Pharm Ther. 2019;44(5):659\u201374.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"1505_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/17512433.2023.2295009","volume":"17","author":"HX Liu","year":"2024","unstructured":"Liu HX, Tang BH, van den Anker J, Hao GX, Zhao W, Zheng Y. Population pharmacokinetics of antibacterial agents in the older population: a literature review. Expert Rev Clin Pharmacol. 2024;17(1):19\u201331.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"1505_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40262-022-01125-2","volume":"61","author":"E Band\u00edn-Vilar","year":"2022","unstructured":"Band\u00edn-Vilar E, Garc\u00eda-Quintanilla L, Castro-Balado A, Zarra-Ferro I, Gonz\u00e1lez-Barcia M, Campos-Toimil M, et al. A review of population pharmacokinetic analyses of linezolid. Clin Pharmacokinet. 2022;61(6):789\u2013817.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1505_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097.","journal-title":"PLoS Med"},{"issue":"7","key":"1505_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/pharmaceutics11070323","volume":"11","author":"JB Bulitta","year":"2019","unstructured":"Bulitta JB, Jiao Y, Landersdorfer CB, Sutaria DS, Tao X, Shin E, et al. Comparable bioavailability and disposition of pefloxacin in patients with cystic fibrosis and healthy volunteers assessed via population pharmacokinetics. Pharmaceutics. 2019;11(7):323.","journal-title":"Pharmaceutics"},{"issue":"11","key":"1505_CR25","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/ppul.24468","volume":"54","author":"P Caceres Guido","year":"2019","unstructured":"Caceres Guido P, Perez M, Halac A, Ferrari M, Ibarra M, Licciardone N, et al. Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis. Pediatr Pulmonol. 2019;54(11):1801\u201310.","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"1505_CR26","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2165\/00003088-200645110-00004","volume":"45","author":"S Hennig","year":"2006","unstructured":"Hennig S, Wainwright CE, Bell SC, Miller H, Friberg LE, Charles BG. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet. 2006;45(11):1099\u2013114.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1505_CR27","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/pharmaceutics11060286","volume":"11","author":"NR Shah","year":"2019","unstructured":"Shah NR, Bulitta JB, Kinzig M, Landersdorfer CB, Jiao Y, Sutaria DS, et al. Novel population pharmacokinetic approach to explain the differences between cystic fibrosis patients and healthy volunteers via protein binding. Pharmaceutics. 2019;11(6):286.","journal-title":"Pharmaceutics"},{"issue":"3","key":"1505_CR28","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1128\/AAC.00936-09","volume":"54","author":"JB Bulitta","year":"2010","unstructured":"Bulitta JB, Landersdorfer CB, H\u00fcttner SJ, Drusano GL, Kinzig M, Holzgrabe U, et al. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother. 2010;54(3):1275\u201382.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1505_CR29","first-page":"2232","volume":"75","author":"S Bui","year":"2020","unstructured":"Bui S, Facchin A, Ha P, Bouchet S, Leroux S, Nacka F, et al. Population pharmacokinetics of ceftazidime in critically ill children: impact of cystic fibrosis. J Antimicrob Chemother. 2020;75(8):2232\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"1505_CR30","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/phar.1320","volume":"33","author":"C Stockmann","year":"2013","unstructured":"Stockmann C, Sherwin CM, Zobell JT, Lubsch L, Young DC, Olson J, et al. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis. Pharmacotherapy. 2013;33(12):1288\u201396.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1505_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jcph.1323","volume":"59","author":"C Stockmann","year":"2019","unstructured":"Stockmann C, Olson J, Rashid J, Lubsch L, Young DC, Hersh AL, et al. An evaluation of vancomycin area under the curve estimation methods for children treated for acute pulmonary exacerbations of cystic fibrosis due to methicillin-resistant Staphylococcus aureus. J Clin Pharmacol. 2019;59(2):198\u2013205.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"1505_CR32","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1093\/jac\/dky328","volume":"73","author":"A Facchin","year":"2018","unstructured":"Facchin A, Bui S, Leroux S, Nacka F, Koehl B, Maksoud E, et al. Variability of ciprofloxacin pharmacokinetics in children: impact on dose range in sickle cell patients. J Antimicrob Chemother. 2018;73(12):3423\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1505_CR33","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1128\/AAC.47.10.3170-3178.2003","volume":"47","author":"S Payen","year":"2003","unstructured":"Payen S, Serreau R, Munck A, Aujard Y, Aigrain Y, Bressolle F, et al. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. Antimicrob Agents Chemother. 2003;47(10):3170\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1505_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1128\/AAC.40.1.29","volume":"40","author":"HG Schaefer","year":"1996","unstructured":"Schaefer HG, Stass H, Wedgwood J, Hampel B, Fischer C, Kuhlmann J, et al. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Antimicrob Agents Chemother. 1996;40(1):29\u201334.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"1505_CR35","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/0091270003254802","volume":"43","author":"P Rajagopalan","year":"2003","unstructured":"Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients. J Clin Pharmacol. 2003;43(7):698\u2013710.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"1505_CR36","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1440-1754.2006.00944.x","volume":"42","author":"J Massie","year":"2006","unstructured":"Massie J, Cranswick N. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. J Paediatr Child Health. 2006;42(10):601\u20135.","journal-title":"J Paediatr Child Health"},{"issue":"4","key":"1505_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40262-013-0036-y","volume":"52","author":"S Hennig","year":"2013","unstructured":"Hennig S, Standing JF, Staatz CE, Thomson AH. Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. Clin Pharmacokinet. 2013;52(4):289\u2013301.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1505_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10928-013-9348-7","volume":"41","author":"CM Sherwin","year":"2014","unstructured":"Sherwin CM, Zobell JT, Stockmann C, McCrory BE, Wisdom M, Young DC, et al. Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis. J Pharmacokinet Pharmacodyn. 2014;41(1):71\u20139.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"10","key":"1505_CR39","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40262-019-00761-5","volume":"58","author":"RL Crass","year":"2019","unstructured":"Crass RL, Pai MP. Optimizing estimated glomerular filtration rate to support adult to pediatric pharmacokinetic bridging studies in patients with cystic fibrosis. Clin Pharmacokinet. 2019;58(10):1323\u201332.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1505_CR40","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1365-2125.2007.03045.x","volume":"65","author":"S Hennig","year":"2008","unstructured":"Hennig S, Norris R, Kirkpatrick CM. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis\u2014a population pharmacokinetic study. Br J Clin Pharmacol. 2008;65(4):502\u201310.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1505_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02377-21","volume":"66","author":"KJ Downes","year":"2022","unstructured":"Downes KJ, Grim A, Shanley L, Rubenstein RC, Zuppa AF, Gastonguay MR. A pharmacokinetic analysis of tobramycin in patients less than five years of age with cystic fibrosis: assessment of target attainment with extended-interval dosing through simulation. Antimicrob Agents Chemother. 2022;66(5): e0237721.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1505_CR42","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jcf.2006.12.007","volume":"6","author":"DJ Touw","year":"2007","unstructured":"Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J Cyst Fibros. 2007;6(5):327\u201333.","journal-title":"J Cyst Fibros"},{"issue":"10","key":"1505_CR43","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00737-21","volume":"65","author":"A Praet","year":"2021","unstructured":"Praet A, Bourguignon L, Vetele F, Breant V, Genestet C, Dumitrescu O, et al. Population pharmacokinetic modeling and dosing simulations of tobramycin in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother. 2021;65(10): e0073721.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1505_CR44","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/jac\/dkw351","volume":"72","author":"KJ Downes","year":"2017","unstructured":"Downes KJ, Dong M, Fukuda T, Clancy JP, Haffner C, Bennett MR, et al. Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. J Antimicrob Chemother. 2017;72(1):254\u201360.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1505_CR45","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051\u201365.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1505_CR46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","volume":"39","author":"G Cheymol","year":"2000","unstructured":"Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39(3):215\u201331.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1505_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1467-3010.1977.tb00966.x","volume":"4","author":"WPT James","year":"1977","unstructured":"James WPT. Research on obesity. Nutr Bull. 1977;4(3):187\u201390.","journal-title":"Nutr Bull"},{"issue":"6","key":"1505_CR48","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0022-3476(84)80479-5","volume":"104","author":"GJ Schwartz","year":"1984","unstructured":"Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr. 1984;104(6):849\u201354.","journal-title":"J Pediatr"},{"issue":"3","key":"1505_CR49","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S0022-3476(85)80697-1","volume":"106","author":"GJ Schwartz","year":"1985","unstructured":"Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr. 1985;106(3):522\u20136.","journal-title":"J Pediatr"},{"issue":"5","key":"1505_CR50","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1365-2125.1981.tb01163.x","volume":"11","author":"TH Hallynck","year":"1981","unstructured":"Hallynck TH, Soep HH, Thomis JA, Boelaert J, Daneels R, Dettli L. Should clearance be normalised to body surface or to lean body mass? Br J Clin Pharmacol. 1981;11(5):523\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1505_CR51","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629\u201337.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1505_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"issue":"6","key":"1505_CR53","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","volume":"11","author":"G D\u00f6ring","year":"2012","unstructured":"D\u00f6ring G, Flume P, Heijerman H, Elborn JS. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012;11(6):461\u201379.","journal-title":"J Cyst Fibros"},{"key":"1505_CR54","unstructured":"Zolin A OA, Jung A, van Rens J, et al. ECFSPR annual report 2021. 2023."},{"key":"1505_CR55","unstructured":"Foundation CF. Methicillin-resistant Staphylococcus aureus (MRSA). https:\/\/www.cff.org\/managing-cf\/methicillin-resistant-staphylococcus-aureus-mrsa."},{"issue":"23","key":"1505_CR56","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1001\/jama.2010.791","volume":"303","author":"EC Dasenbrook","year":"2010","unstructured":"Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA. 2010;303(23):2386\u201392.","journal-title":"JAMA"},{"issue":"6","key":"1505_CR57","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jcf.2017.04.010","volume":"16","author":"MT Jennings","year":"2017","unstructured":"Jennings MT, Dasenbrook EC, Lechtzin N, Boyle MP, Merlo CA. Risk factors for persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. J Cyst Fibros. 2017;16(6):681\u20136.","journal-title":"J Cyst Fibros"},{"key":"1505_CR58","unstructured":"Canada CF. Antibiotic dosing guideline for cystic fibrosis. 2021. https:\/\/www.cysticfibrosis.ca\/uploads\/Antibiotic%20Dosing%20Guideline%20Aug%202021.pdf."},{"key":"1505_CR59","unstructured":"Foundation CF. Antibiotics. 2024. https:\/\/www.cff.org\/managing-cf\/antibiotics."},{"key":"1505_CR60","unstructured":"UK CFT. Antibiotic treatment for cystic fibrosis. 2009. https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2020-11\/Anitbiotic%20Treatment.pdf."},{"issue":"2","key":"1505_CR61","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","volume":"17","author":"C Castellani","year":"2018","unstructured":"Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153\u201378.","journal-title":"J Cyst Fibros"},{"issue":"Suppl 3","key":"1505_CR62","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/S1098-3597(03)90027-5","volume":"5","author":"KA Sprandel","year":"2003","unstructured":"Sprandel KA, Rodvold KA. Safety and tolerability of fluoroquinolones. Clin Cornerstone. 2003;5(Suppl 3):S29-36.","journal-title":"Clin Cornerstone"},{"issue":"2","key":"1505_CR63","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1517\/14740338.4.2.299","volume":"4","author":"A Melhus","year":"2005","unstructured":"Melhus A. Fluoroquinolones and tendon disorders. Expert Opin Drug Saf. 2005;4(2):299\u2013309.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"1505_CR64","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1124\/jpet.103.057984","volume":"308","author":"F Pouzaud","year":"2004","unstructured":"Pouzaud F, Bernard-Beaubois K, Thevenin M, Warnet JM, Hayem G, Rat P. In vitro discrimination of fluoroquinolones toxicity on tendon cells: involvement of oxidative stress. J Pharmacol Exp Ther. 2004;308(1):394\u2013402.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1505_CR65","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2131\/jts.36.339","volume":"36","author":"E Olcay","year":"2011","unstructured":"Olcay E, Beytemur O, Kaleagasioglu F, Gulmez T, Mutlu Z, Olgac V. Oral toxicity of pefloxacin, norfloxacin, ofloxacin and ciprofloxacin: comparison of biomechanical and histopathological effects on Achilles tendon in rats. J Toxicol Sci. 2011;36(3):339\u201345.","journal-title":"J Toxicol Sci"},{"issue":"10","key":"1505_CR66","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s40261-018-0684-7","volume":"38","author":"DR Morales","year":"2018","unstructured":"Morales DR, Slattery J, Pinheiro L, Kurz X, Hedenmalm K. Indications for systemic fluoroquinolone therapy in Europe and prevalence of primary-care prescribing in France, Germany and the UK: descriptive population-based study. Clin Drug Investig. 2018;38(10):927\u201333.","journal-title":"Clin Drug Investig"},{"key":"1505_CR67","unstructured":"Summary of the EMA public hearing on quinolone and fluoroquinolone antibiotics. 2018."},{"issue":"4","key":"1505_CR68","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40262-020-00970-3","volume":"60","author":"M El Hassani","year":"2021","unstructured":"El Hassani M, Caissy JA, Marsot A. Antibiotics in adult cystic fibrosis patients: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2021;60(4):447\u201370.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1505_CR69","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40262-018-0641-x","volume":"57","author":"SM Illamola","year":"2018","unstructured":"Illamola SM, Sherwin CM, van Hasselt JGC. Clinical pharmacokinetics of amikacin in pediatric patients: a comprehensive review of population pharmacokinetic analyses. Clin Pharmacokinet. 2018;57(10):1217\u201328.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1505_CR70","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40272-023-00564-z","volume":"25","author":"S Matcha","year":"2023","unstructured":"Matcha S, Dillibatcha J, Raju AP, Chaudhari BB, Moorkoth S, Lewis LE, et al. Predictive performance of population pharmacokinetic models for amikacin in term neonates. Paediatr Drugs. 2023;25(3):365\u201375.","journal-title":"Paediatr Drugs"},{"issue":"6","key":"1505_CR71","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40262-020-00866-2","volume":"59","author":"A Aljutayli","year":"2020","unstructured":"Aljutayli A, Marsot A, Nekka F. An update on population pharmacokinetic analyses of vancomycin, part I: in adults. Clin Pharmacokinet. 2020;59(6):671\u201398.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1505_CR72","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3390\/antibiotics10050507","volume":"10","author":"A Duong","year":"2021","unstructured":"Duong A, Simard C, Wang YL, Williamson D, Marsot A. Aminoglycosides in the intensive care unit: what is new in population PK modeling? Antibiotics (Basel). 2021;10(5):507.","journal-title":"Antibiotics (Basel)."},{"issue":"2","key":"1505_CR73","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/bcp.15933","volume":"90","author":"AM Junkert","year":"2024","unstructured":"Junkert AM, Lazo REL, Deffert F, Carneiro J, Borba HHL, de Campos ML, et al. Pharmacokinetics of oral ciprofloxacin in adult patients: a scoping review. Br J Clin Pharmacol. 2024;90(2):528\u201347.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1505_CR74","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1097\/MCP.0b013e328365af49","volume":"19","author":"K McIntyre","year":"2013","unstructured":"McIntyre K. Gender and survival in cystic fibrosis. Curr Opin Pulm Med. 2013;19(6):692\u20137.","journal-title":"Curr Opin Pulm Med"},{"issue":"4","key":"1505_CR75","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ppul.22967","volume":"49","author":"NB Sweezey","year":"2014","unstructured":"Sweezey NB, Ratjen F. The cystic fibrosis gender gap: potential roles of estrogen. Pediatr Pulmonol. 2014;49(4):309\u201317.","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"1505_CR76","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00018-016-2393-9","volume":"74","author":"C Castellani","year":"2017","unstructured":"Castellani C, Assael BM. Cystic fibrosis: a clinical view. Cell Mol Life Sci. 2017;74(1):129\u201340.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"1505_CR77","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40262-018-0678-x","volume":"58","author":"JB Bulitta","year":"2019","unstructured":"Bulitta JB, Jiao Y, Drescher SK, Oliver A, Louie A, Moya B, et al. Four decades of \u03b2-lactam antibiotic pharmacokinetics in cystic fibrosis. Clin Pharmacokinet. 2019;58(2):143\u201356.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1505_CR78","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2165\/00003088-199835060-00003","volume":"35","author":"DJ Touw","year":"1998","unstructured":"Touw DJ, Vinks AA, Mouton JW, Horrevorts AM. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. Clin Pharmacokinet. 1998;35(6):437\u201359.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1505_CR79","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.idc.2023.12.002","volume":"38","author":"TS Murray","year":"2024","unstructured":"Murray TS, Stanley G, Koff JL. Novel approaches to multidrug-resistant infections in cystic fibrosis. Infect Dis Clin North Am. 2024;38(1):149\u201362.","journal-title":"Infect Dis Clin North Am"},{"issue":"6","key":"1505_CR80","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1128\/AAC.02654-15","volume":"60","author":"C Bloomfield","year":"2016","unstructured":"Bloomfield C, Staatz CE, Unwin S, Hennig S. Assessing predictive performance of published population pharmacokinetic models of intravenous tobramycin in pediatric patients. Antimicrob Agents Chemother. 2016;60(6):3407\u201314.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1505_CR81","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1093\/cid\/ciz1163","volume":"71","author":"SDT Sassen","year":"2020","unstructured":"Sassen SDT, Math\u00f4t RAA, Pieters R, de Haas V, Kaspers GJL, van den Bos C, et al. Population pharmacokinetics and pharmacodynamics of ciprofloxacin prophylaxis in pediatric acute lymphoblastic leukemia patients. Clin Infect Dis. 2020;71(8):e281\u20138.","journal-title":"Clin Infect Dis"},{"key":"1505_CR82","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00517-18","author":"K Meesters","year":"2018","unstructured":"Meesters K, Michelet R, Mauel R, Raes A, Van Bocxlaer J, Vande Walle J, et al. Results of a multicenter population pharmacokinetic study of ciprofloxacin in children with complicated urinary tract infection. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.00517-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1505_CR83","unstructured":"Reyhanoglu G, Reddivari AKR. Tobramycin. StatPearls. Treasure Island (FL) ineligible companies. StatPearls Publishing Copyright 2024, StatPearls Publishing LLC.; 2024."},{"issue":"Suppl D","key":"1505_CR84","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/jac\/14.suppl_D.43","volume":"14","author":"RC Moellering Jr","year":"1984","unstructured":"Moellering RC Jr. Pharmacokinetics of vancomycin. J Antimicrob Chemother. 1984;14(Suppl D):43\u201352.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1505_CR85","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/psp4.13131","volume":"13","author":"RL Decker","year":"2024","unstructured":"Decker RL, Steven Ernest C Jr, Radtke DB, Wang R, Ara\u00fajo J, Keller SY, et al. A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis. CPT Pharmacometr Syst Pharmacol. 2024;13(6):970\u201381.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"issue":"9","key":"1505_CR86","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/jps.23574","volume":"102","author":"N Holford","year":"2013","unstructured":"Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102(9):2941\u201352.","journal-title":"J Pharm Sci"},{"key":"1505_CR87","unstructured":"FDA. Drug databases: Drugs@FDA: FDA-approved drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=212273."},{"key":"1505_CR88","unstructured":"Canada CF. Trikafta approved for 2 to 5-year-olds. https:\/\/cysticfibrosis.ca\/news\/trikafta-approved-for-2-to-5-year-olds."},{"key":"1505_CR89","unstructured":"Canada Go. Drug and health product portal: regulatory decision summary for Trikafta. https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/RDS00846."},{"key":"1505_CR90","unstructured":"EMA. Kaftrio (ivacaftor\/tezacaftor\/elexacaftor). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kaftrio#news-on."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01505-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01505-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01505-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:03:52Z","timestamp":1746792232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01505-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1505"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01505-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"31 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aysenur Yaliniz received scholarships from the Faculty of Pharmacy of Universit\u00e9 de Montr\u00e9al and the R\u00e9seau de recherche en Sant\u00e9 Respiratoire du Qu\u00e9bec (RSRQ). Mehdi El Hassani acknowledges support from the Fonds de Recherche Qu\u00e9bec\u2014Sant\u00e9 (FRQS) (doctoral training scholarship). Am\u00e9lie Marsot received salary support from the Fonds de Recherche du Qu\u00e9bec\u2014Sant\u00e9 (FRQS).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Aysenur Yaliniz, Mehdi El Hassani and Ana C. Blanchard declare no conflicts of interest. Amelie Marsot is an Editorial Board member of Clinical Pharmacokinetics. Amelie Marsot was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"A.Y. performed the literature search. A.Y. analyzed the data. A.Y. wrote the manuscript. M.E.H., A.B., and A.M. validated the manuscript. A.M. supervised the work. All authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}